Q-omics provides the consensus-scored MPIG6B profile across patient tissues and cancer cell-line models. MPIG6B expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, MPIG6B is differentially expressed in 10, with the highest sampling consensus in LUAD. Additionally, MPIG6B RNA expression shows 15,542 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCS, LUAD, and TGCT as cancer lineages where MPIG6B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MPIG6B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MPIG6B survival associations across molecular data types. MPIG6B RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MPIG6B RNA expression–survival associations across cancer types. High MPIG6B expression shows unfavorable associations in LGG, READ, ACC and BLCA, but favorable associations in UCS and LUAD. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for MPIG6B RNA expression.
This table summarizes MPIG6B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 2. The strongest signals are observed in LUAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for MPIG6B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MPIG6B shows lower tumor expression in LUAD, KICH, LUSC and UCEC and higher tumor expression in COAD and THCA. The LUAD box plot shows higher MPIG6B RNA expression in normal versus tumor tissue (log2 FC = −1.334, t-test p < 0.001).
This table shows molecular features associated with MPIG6B in patient tissues and cancer cell lines. In patient samples, MPIG6B shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, MPIG6B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and SOFT_TISSUE.
